Business Description
Vanda Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US9216591084
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 44.17 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.43 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 2.34 | |||||
Beneish M-Score | -1.45 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.4 | |||||
3-Year EPS without NRI Growth Rate | -54.3 | |||||
3-Year FCF Growth Rate | -38 | |||||
3-Year Book Growth Rate | 4.7 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.91 | |||||
9-Day RSI | 41.47 | |||||
14-Day RSI | 47.26 | |||||
6-1 Month Momentum % | 23.68 | |||||
12-1 Month Momentum % | -22.31 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.71 | |||||
Quick Ratio | 4.69 | |||||
Cash Ratio | 4.22 | |||||
Days Inventory | 32.82 | |||||
Days Sales Outstanding | 65.05 | |||||
Days Payable | 113.58 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.6 | |||||
Shareholder Yield % | 0.46 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 92.42 | |||||
Operating Margin % | -14.18 | |||||
Net Margin % | -2.75 | |||||
FCF Margin % | -6.64 | |||||
ROE % | -0.9 | |||||
ROA % | -0.76 | |||||
ROIC % | -15.12 | |||||
ROC (Joel Greenblatt) % | -261.75 | |||||
ROCE % | -4.53 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shiller PE Ratio | 15.15 | |||||
PS Ratio | 1.81 | |||||
PB Ratio | 0.6 | |||||
Price-to-Tangible-Book | 0.76 | |||||
EV-to-EBIT | 2.4 | |||||
EV-to-EBITDA | 2.93 | |||||
EV-to-Revenue | -0.34 | |||||
EV-to-FCF | 5.14 | |||||
Price-to-Projected-FCF | 0.42 | |||||
Price-to-Median-PS-Value | 0.46 | |||||
Price-to-Net-Current-Asset-Value | 0.98 | |||||
Price-to-Net-Cash | 1.14 | |||||
Earnings Yield (Greenblatt) % | 41.67 | |||||
FCF Yield % | -3.62 | |||||
Forward Rate of Return (Yacktman) % | -4.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Vanda Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 164.059 | ||
EPS (TTM) (€) | -0.071 | ||
Beta | 0.08 | ||
Volatility % | 52.01 | ||
14-Day RSI | 47.26 | ||
14-Day ATR (€) | 0.217385 | ||
20-Day SMA (€) | 5.541 | ||
12-1 Month Momentum % | -22.31 | ||
52-Week Range (€) | 3.04 - 6.15 | ||
Shares Outstanding (Mil) | 58.2 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Vanda Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Vanda Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Vanda Pharmaceuticals Inc Frequently Asked Questions
What is Vanda Pharmaceuticals Inc(STU:VM4)'s stock price today?
When is next earnings date of Vanda Pharmaceuticals Inc(STU:VM4)?
Does Vanda Pharmaceuticals Inc(STU:VM4) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |